Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 47Gastrointestinal 4Thoracic 2Gynecologic 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ado-Trastuzumab Emtansine × Thoracic × Clear all
NCT05650879 2025-07-15

HER2

Enliven Therapeutics

Phase 1 Active not recruiting
198 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02289833 2019-08-07

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Hoffmann-La Roche

Phase 2 Completed
49 enrolled 22 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡